MKI67 and breast cancer: In addition, BC patients with the TT and CT genotypes of the rs5746136 variant showed BC susceptibility with Ki-67 (≥20%) (OR 2.9, 95% CI 1.16–7.36, p = 0.022) and luminal A type (OR 16, 95% CI 0.46–0.21, p = 0.041), respectively, and the dominant model CTTT for a chemotherapy partial response (OR 2.37.5, 95% CI 1.06–5.32, p = 0.035).